Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Veracyte Inc (NASDAQ: VCYT) was $26.81 for the day, up 1.36% from the previous closing price of $26.45. In other words, the price has increased by $1.36 from its previous closing price. On the day, 0.92 million shares were traded. VCYT stock price reached its highest trading level at $26.83 during the session, while it also had its lowest trading level at $26.015.
Ratios:
Our analysis of VCYT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 26.76. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 5.10. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on March 20, 2025, initiated with a Buy rating and assigned the stock a target price of $45.
On December 05, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $38 to $37.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $50.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 13 ’25 when EASTHAM KARIN sold 4,590 shares for $26.66 per share. The transaction valued at 122,388 led to the insider holds 13,907 shares of the business.
Bhanji Muna sold 4,589 shares of VCYT for $122,367 on Jun 13 ’25. The Director now owns 29,989 shares after completing the transaction at $26.67 per share. On Jun 13 ’25, another insider, KARIN EASTHAM, who serves as the Director of the company, bought 4,590 shares for $26.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 2099614336 and an Enterprise Value of 1862760704. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 63.91, and their Forward P/E ratio for the next fiscal year is 37.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.53 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 4.02 whereas that against EBITDA is 29.909.
Stock Price History:
The Beta on a monthly basis for VCYT is 2.09, which has changed by 0.2371943 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $47.32, while it has fallen to a 52-week low of $19.73. The 50-Day Moving Average of the stock is -6.84%, while the 200-Day Moving Average is calculated to be -23.16%.
Shares Statistics:
VCYT traded an average of 1.01M shares per day over the past three months and 835610 shares per day over the past ten days. A total of 78.31M shares are outstanding, with a floating share count of 77.13M. Insiders hold about 1.52% of the company’s shares, while institutions hold 108.03% stake in the company. Shares short for VCYT as of 1749772800 were 5942060 with a Short Ratio of 5.91, compared to 1747267200 on 5212781. Therefore, it implies a Short% of Shares Outstanding of 5942060 and a Short% of Float of 8.469999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
